Roche Beats Expectations on Strong Performance from Key Drugs
Dow Jones14:58
0655 GMT - Roche Holding reported stronger-than-expected sales growth for the third quarter due to its pharmaceutical division, where most key drugs performed better than anticipated, Vontobel's Stefan Schneider says in a research note. Despite sales beating forecasts, the Swiss drugmaker left its full-year guidance unchanged, which shouldn't come as a surprise, the analyst says. The pharma business reported sales growth that was ahead of both Vontobel's and consensus estimates, while the group's diagnostics division fell short of expectations, he adds. With the exception of Ocrevus, other key drugs for Roche such as Hemlibra, Vabysmo and Phesgo beat expectations, according to Vontobel.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments